Wedbush has reaffirmed its Outperform rating for Rocket Pharmaceuticals (RCKT) with a 12-month price target of $16, following the company’s recent accelerated FDA approval for Kresladi, a gene therapy for Severe Leukocyte Adhesion Deficiency Type I. The approval, bolstered by strong clinical data showing 100% overall survival at 12 months, positions Rocket favorably in the rare disease market. The company also received a Rare Pediatric Disease Priority Review Voucher, potentially adding around $200 million in non-dilutive funding to its balance sheet.

This FDA approval is a pivotal moment for Rocket, reflecting effective management execution and the potential for minimal payer resistance given the drug’s compelling efficacy. Despite this positive development, RCKT’s stock has seen a nearly 27% decline since the approval announcement, currently trading at $3.44.

Investors should note that the PRV could significantly extend Rocket’s financial runway, potentially through 2028, making this an opportune time to reassess the stock’s value proposition.

Source: nasdaq.com